Cubital tunnel syndrome is a disease in which ulnar nerve is compressed by its surrounding tissues,and its main clinical manifestations are pain,sensory disturbance and dyskinesia.Its incidence rate is the second high...Cubital tunnel syndrome is a disease in which ulnar nerve is compressed by its surrounding tissues,and its main clinical manifestations are pain,sensory disturbance and dyskinesia.Its incidence rate is the second highest among peripheral nerve entrapment diseases,and it is one of the common clinical diseases.The theory of liver,spleen and kidney can guide the treatment of cubital tunnel syndrome with traditional Chinese medicine and acupuncture.By discussing the traditional Chinese medicine(TCM)pathogenesis and treatment principles of cubital tunnel syndrome,it provides modern medical theoretical support for TCM treatment of cubital tunnel syndrome.展开更多
目的:运用网络药理学和分子对接的方法,探索健脾疏肝方治疗非酒精性脂肪性肝病(non-alcoholic fatty liver disease,NAFLD)的潜在机制。方法:利用中药系统药理学数据库与分析平台(traditional Chinese medicine systems pharmacology,TC...目的:运用网络药理学和分子对接的方法,探索健脾疏肝方治疗非酒精性脂肪性肝病(non-alcoholic fatty liver disease,NAFLD)的潜在机制。方法:利用中药系统药理学数据库与分析平台(traditional Chinese medicine systems pharmacology,TCMSP)和已发表的文献筛选健脾疏肝方的活性化合物和潜在作用靶点,利用人类基因数据库(GeneCards)、在线人类孟德尔遗传数据库(online mendelian inheritance in man,OMIM)和药物靶标数据库(therapeutic target database,TTD)筛选NAFLD的相关靶点,预测健脾疏肝方治疗NAFLD的潜在靶点。利用STRING数据库和Cytoscape软件构建共同靶标的PPI网络。利用DAVID数据库及微生信云平台进行基因本体(gene ontology,GO)和京都基因与基因组百科全书(kyoto encyclopedia of genes and genomes,KEGG)通路富集分析。最后利用AutoDock Vina和Pymol软件对核心靶点和主要活性化合物进行分子对接。结果:共筛选出117个活性化合物和279个潜在靶标,其中槲皮素(Quercetin)、木犀草素(luteolin)、豆甾醇(Stigmasterol)、山柰酚(kaempferol)为健脾疏肝方主要活性化合物。PPI网络显示白细胞介素6(interleukin-6,IL-6)、肿瘤坏死因子(tumor necrosis factor,TNF)、信号转换器和转录激活因子3(signal transducer and activator of transcription 3,STAT3)、前列腺素内过氧化物合酶2(prostaglandin-endoperoxide synthase 2,PTGS2)和血管内皮生长因子A(vascular endothelial growth factor,VEGFA)是关键靶蛋白。KEGG通路富集分析结果显示,癌症、TNF、乙型病毒性肝炎、MAPK、PI3K-Akt及NAFLD信号通路可能是健脾疏肝方干预NAFLD的潜在机制。分子对接结果表明,健脾疏肝方主要活性化合物与核心靶标具有良好的结合能力。结论:健脾疏肝方可以通过多组分、多靶点及多通路起到干预NAFLD的作用。展开更多
目的探究补气健脾疏肝法联合生物反馈治疗出口梗阻型便秘的临床疗效。方法选择河北省石家庄市中医院肛肠科气虚秘型出口梗阻型便秘患者80例作为研究对象,根据随机数字法分为试验组与对照组,两组各40例。对照组予以生物反馈治疗,30 min/...目的探究补气健脾疏肝法联合生物反馈治疗出口梗阻型便秘的临床疗效。方法选择河北省石家庄市中医院肛肠科气虚秘型出口梗阻型便秘患者80例作为研究对象,根据随机数字法分为试验组与对照组,两组各40例。对照组予以生物反馈治疗,30 min/次,每周3次;试验组在对照组基础上予补气健脾疏肝法治疗,每日1剂,水煎取汁400 mL,分早晚两次温服。两组均连续治疗4周。观察两组治疗前后的中医临床疗效、证候评分、肛门疼痛情况、生活质量及安全性。结果治疗后,试验组的临床总有效率(97.5%)优于对照组(72.5%)(P<0.05)。治疗后,与治疗前比较,两组排便频率、排便困难、粪便性状、排便时间、肛门堵塞感、排便不尽感的中医证候评分、疼痛数字评定量表(numerical rating scale,NRS)、便秘患者生活质量自评量表(patient assessment of constipation quality of life questionnaire,PAC-QOL)评分均下降(P<0.05);与对照组比较,试验组各项证候评分、NRS评分、PAC-QOL评分较低(P<0.05)。与对照组相比,试验组不良反应较低(P<0.05)。结论生物反馈联合补气健脾疏肝法治疗出口梗阻型便秘疗效确切,可有效缓解患者的临床症状,减轻患者的肛门疼痛,并提高患者的生活质量。展开更多
基金TCM science and Technology project of Hebei Provincial Administration of Traditional Chinese Medicine in 2021(No.2021352):The therapeutic effect of cubital tunnel expansion plasty combined with Huangqi Guizhi Wuwu Decoction on cubital tunnel syndrome。
文摘Cubital tunnel syndrome is a disease in which ulnar nerve is compressed by its surrounding tissues,and its main clinical manifestations are pain,sensory disturbance and dyskinesia.Its incidence rate is the second highest among peripheral nerve entrapment diseases,and it is one of the common clinical diseases.The theory of liver,spleen and kidney can guide the treatment of cubital tunnel syndrome with traditional Chinese medicine and acupuncture.By discussing the traditional Chinese medicine(TCM)pathogenesis and treatment principles of cubital tunnel syndrome,it provides modern medical theoretical support for TCM treatment of cubital tunnel syndrome.
文摘目的:运用网络药理学和分子对接的方法,探索健脾疏肝方治疗非酒精性脂肪性肝病(non-alcoholic fatty liver disease,NAFLD)的潜在机制。方法:利用中药系统药理学数据库与分析平台(traditional Chinese medicine systems pharmacology,TCMSP)和已发表的文献筛选健脾疏肝方的活性化合物和潜在作用靶点,利用人类基因数据库(GeneCards)、在线人类孟德尔遗传数据库(online mendelian inheritance in man,OMIM)和药物靶标数据库(therapeutic target database,TTD)筛选NAFLD的相关靶点,预测健脾疏肝方治疗NAFLD的潜在靶点。利用STRING数据库和Cytoscape软件构建共同靶标的PPI网络。利用DAVID数据库及微生信云平台进行基因本体(gene ontology,GO)和京都基因与基因组百科全书(kyoto encyclopedia of genes and genomes,KEGG)通路富集分析。最后利用AutoDock Vina和Pymol软件对核心靶点和主要活性化合物进行分子对接。结果:共筛选出117个活性化合物和279个潜在靶标,其中槲皮素(Quercetin)、木犀草素(luteolin)、豆甾醇(Stigmasterol)、山柰酚(kaempferol)为健脾疏肝方主要活性化合物。PPI网络显示白细胞介素6(interleukin-6,IL-6)、肿瘤坏死因子(tumor necrosis factor,TNF)、信号转换器和转录激活因子3(signal transducer and activator of transcription 3,STAT3)、前列腺素内过氧化物合酶2(prostaglandin-endoperoxide synthase 2,PTGS2)和血管内皮生长因子A(vascular endothelial growth factor,VEGFA)是关键靶蛋白。KEGG通路富集分析结果显示,癌症、TNF、乙型病毒性肝炎、MAPK、PI3K-Akt及NAFLD信号通路可能是健脾疏肝方干预NAFLD的潜在机制。分子对接结果表明,健脾疏肝方主要活性化合物与核心靶标具有良好的结合能力。结论:健脾疏肝方可以通过多组分、多靶点及多通路起到干预NAFLD的作用。
文摘目的探究补气健脾疏肝法联合生物反馈治疗出口梗阻型便秘的临床疗效。方法选择河北省石家庄市中医院肛肠科气虚秘型出口梗阻型便秘患者80例作为研究对象,根据随机数字法分为试验组与对照组,两组各40例。对照组予以生物反馈治疗,30 min/次,每周3次;试验组在对照组基础上予补气健脾疏肝法治疗,每日1剂,水煎取汁400 mL,分早晚两次温服。两组均连续治疗4周。观察两组治疗前后的中医临床疗效、证候评分、肛门疼痛情况、生活质量及安全性。结果治疗后,试验组的临床总有效率(97.5%)优于对照组(72.5%)(P<0.05)。治疗后,与治疗前比较,两组排便频率、排便困难、粪便性状、排便时间、肛门堵塞感、排便不尽感的中医证候评分、疼痛数字评定量表(numerical rating scale,NRS)、便秘患者生活质量自评量表(patient assessment of constipation quality of life questionnaire,PAC-QOL)评分均下降(P<0.05);与对照组比较,试验组各项证候评分、NRS评分、PAC-QOL评分较低(P<0.05)。与对照组相比,试验组不良反应较低(P<0.05)。结论生物反馈联合补气健脾疏肝法治疗出口梗阻型便秘疗效确切,可有效缓解患者的临床症状,减轻患者的肛门疼痛,并提高患者的生活质量。